Tiger Trial Shows Efficacy for New Class of Radially Adjustable Stentrievers in Acute Ischemic Stroke

Data from a prospective clinical trial (NCT03474549) showed treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO) with a novel, radially adjustable stentriever (Tigertriever; Rapid Medical, Sunrise, FL) was superior to that of established stentrievers. With the radially adjustable, fully visible, stentriever, the operator can radial expansion with the diameter of the target vessel. 

As published in Stroke, successful reperfusion occurred in 84.6% (98/117) of those treated within 3 passes of the radially adjustable stentriever, which was superior to the 73.4% historical rate (P<.01). Successful reperfusion was defined as a modified Thrombolysis in Cerebral Ischemia (mTICI) score 2b-3.The first-pass successful reperfusion rate was 57.8%. After all interventions, including those in 43 individuals in a lead-in phase of the study, successful reperfusion occurred in 95.7% of treated individuals and excellent reperfusion (mTICI 2c-3) occured in 71.8%). 

The radially adjustable stentriever had a similar safety profile to established stentrievers. Symptomatic intracranial hemorrhage (sICH) or death occurred in 18.1% of participants compared with the 20.4% historical rate (noninferiority P=.004) and good clinical outcome in 90 days was achieved for 58% of participants.